Stem Cell Therapy for Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic immune-mediated disease affecting the central nervous system. The immune system attacks the protective covering of nerve fibers, known as myelin, which can disrupt communication between the brain, spinal cord, and the rest of the body. The symptoms and progression of MS can vary significantly depending on the location and extent of neurological damage.
Common symptoms may include vision problems, numbness, weakness, balance and walking difficulties, muscle spasms, fatigue, bladder or bowel dysfunction, and cognitive or mood changes.
Although there is currently no cure for MS, established treatments can reduce relapses, control disease activity, slow progression in appropriate patients, and manage symptoms.
Types of Multiple Sclerosis
MS is generally classified according to its clinical course, including:
- Relapsing-Remitting Multiple Sclerosis (RRMS).
- Secondary Progressive Multiple Sclerosis (SPMS).
- Primary Progressive Multiple Sclerosis (PPMS).
Relapsing-remitting MS is the most common form and is characterized by episodes of new or worsening neurological symptoms followed by periods of partial or complete recovery.
How Is Multiple Sclerosis Diagnosed?
There is no single test that can diagnose MS in every patient. Diagnosis is based on a combination of clinical findings, neurological examination, imaging, and laboratory investigations.
The diagnostic evaluation may include:
- Detailed medical and neurological history.
- Comprehensive neurological examination.
- Magnetic Resonance Imaging (MRI) of the brain and spinal cord.
- Blood tests to exclude conditions that can mimic MS.
- Cerebrospinal fluid analysis through lumbar puncture when indicated.
- Ongoing assessment of neurological symptoms and disease activity.
Accurate diagnosis is essential for distinguishing MS from other neurological or autoimmune disorders with similar clinical presentations.
Stem Cell Therapy and Multiple Sclerosis
Autologous Hematopoietic Stem Cell Transplantation (AHSCT) has become an important area of clinical research and treatment for selected patients with highly active Multiple Sclerosis.
AHSCT is different from simply administering stem cells with the expectation of directly regenerating damaged nerves. The treatment uses the patient’s own hematopoietic stem cells to support immune system reconstitution following an intensive conditioning treatment.
The primary therapeutic objective is to reset or significantly modify the immune response responsible for inflammatory MS activity, rather than directly replace damaged neurons or myelin.
Who May Be Considered for AHSCT?
AHSCT is not appropriate for every person with Multiple Sclerosis. Patient selection is an essential component of treatment.
Factors that may be considered include:
- Age and overall health.
- Type of MS.
- Disease activity and progression.
- Frequency and severity of relapses.
- MRI evidence of active inflammatory disease.
- Response to previous disease-modifying therapies.
- Level of neurological disability.
- Ability to safely undergo conditioning and transplantation.
The 2025 ECTRIMS/EBMT recommendations identify AHSCT as a treatment option particularly for selected patients with aggressive, relapsing MS that remains active despite high-efficacy disease-modifying therapy.
Potential Goals of Stem Cell Transplantation
For appropriately selected patients, the primary goal of AHSCT is to achieve sustained control of inflammatory disease activity.
Potential treatment goals include:
- Reducing the frequency of relapses.
- Limiting the development of new MRI lesions.
- Suppressing inflammatory disease activity.
- Preserving neurological function.
- Reducing the risk of further disability in appropriate patients.
- Achieving prolonged periods without significant disease activity.
Clinical outcomes vary depending on disease characteristics, patient selection, treatment protocols, and the presence of ongoing inflammatory activity.
Regen's Approach to Neurological Care
At Regen, neurological conditions require an individualized assessment of the patient’s diagnosis, disease activity, previous treatments, functional status, and overall health.
A comprehensive program may include:
- Neurological evaluation.
- Review of previous treatments and medical history.
- Assessment of disease activity using appropriate investigations.
- Review of MRI findings when available.
- Evaluation of neurological function and disability.
- Discussion of appropriate regenerative medicine options for selected patients.
- Multidisciplinary follow-up and rehabilitation planning.
- Physical and neurological rehabilitation according to individual needs.
Any cellular therapy should be considered according to the patient’s clinical condition, available evidence, and specialist medical assessment.
The Importance of Rehabilitation
Neurological rehabilitation remains an important part of comprehensive MS care, including for patients receiving disease-modifying or cellular therapies.
Rehabilitation may include:
- Physical therapy.
- Strength and flexibility exercises.
- Balance and gait training.
- Occupational therapy.
- Management of muscle spasticity.
- Support for daily functional activities.
- Strategies for managing fatigue and mobility difficulties.
A multidisciplinary approach can help address the wide range of physical, functional, and psychological effects associated with MS.
What Does the Research Say?
Current evidence indicates that AHSCT can provide significant control of inflammatory disease activity in carefully selected patients with highly active relapsing MS. The strongest evidence is generally seen in patients with active inflammatory disease, while the benefit is less established in advanced progressive disease dominated by neurodegeneration rather than active inflammation.
The 2025 ECTRIMS/EBMT consensus recommendations provide guidance on patient selection, treatment pathways, monitoring, rehabilitation, and supportive care surrounding AHSCT. They also emphasize that the treatment should be performed in specialized centers with appropriate multidisciplinary expertise.
Further research is still needed to establish optimal treatment timing, identify the patients most likely to benefit, refine treatment protocols, and evaluate long-term outcomes.
It is also important to distinguish AHSCT from other forms of stem cell therapy. Different cellular therapies do not have the same level of clinical evidence, and their safety and effectiveness should be evaluated separately.